drugset / Trial / NCT02976116
A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
Fruquintinib in combination with Gefitinib as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring activating EGFR mutations : a single-arm, multicenter, phase II study
Timeline
- Start
- 2016-12
- Primary completion
- 2019-06-28
- Completion
- 2019-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | — | Oral |
| Subject | Gefitinib | Small molecule | — | Oral |